Literature DB >> 2192014

Chronic treatment of rats with SCH-23390 or raclopride does not affect the concentrations of DARPP-32 or its mRNA in dopamine-innervated brain regions.

J A Grebb1, J A Girault, M Ehrlich, P Greengard.   

Abstract

DARPP-32 (dopamine- and cyclic AMP-regulated phosphoprotein, Mr = 32,000, as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis) is a neuronal phosphoprotein that is enriched in neurons which possess dopamine D1 receptors, particularly striatonigral neurons. In rat brain slices, the phosphorylation state of DARPP-32 is regulated by dopamine, acting through the dopamine D1 receptor and the adenylyl cyclase system. This study reports that chronic blockade (21 days) of either dopamine D1 receptors by SCH-23390 or dopamine D2 receptors by raclopride does not affect the concentrations of DARPP-32 in specific rat brain regions (striatum, thalamus, hippocampus, frontal cerebral cortical pole). Northern blot analysis indicates that the steady-state level of DARPP-32 mRNA in striatum is also unchanged by these treatments.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2192014     DOI: 10.1111/j.1471-4159.1990.tb08839.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  7 in total

1.  Egr-1 induces DARPP-32 expression in striatal medium spiny neurons via a conserved intragenic element.

Authors:  Serene Keilani; Samira Chandwani; Georgia Dolios; Alexey Bogush; Heike Beck; Antonis K Hatzopoulos; Gadiparthi N Rao; Elizabeth A Thomas; Rong Wang; Michelle E Ehrlich
Journal:  J Neurosci       Date:  2012-05-16       Impact factor: 6.167

Review 2.  Interactions between D1 and D2 dopamine receptor family agonists and antagonists: the effects of chronic exposure on behavior and receptor binding in rats and their clinical implications.

Authors:  A R Braun; M Laruelle; M M Mouradian
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

3.  Detailed DARPP-32 expression profiles in postmortem brains from patients with schizophrenia: an immunohistochemical study.

Authors:  Yasuto Kunii; Keiko Ikemoto; Akira Wada; Qiaohui Yang; Takashi Kusakabe; Toshimitsu Suzuki; Shin-Ichi Niwa
Journal:  Med Mol Morphol       Date:  2011-12-17       Impact factor: 2.309

4.  DARPP-32 and NCS-1 expression is not altered in brains of rats treated with typical or atypical antipsychotics.

Authors:  Bruno R Souza; Bernardo S Motta; Daniela V F Rosa; Karen C L Torres; Adalberto A Castro; Clarissa M Comim; André M Sampaio; Fabrício F Lima; Andreas Jeromin; João Quevedo; Marco A Romano-Silva
Journal:  Neurochem Res       Date:  2007-08-31       Impact factor: 3.996

5.  Beyond the dopamine receptor: regulation and roles of serine/threonine protein phosphatases.

Authors:  Sven Ivar Walaas; Hugh Caroll Hemmings; Paul Greengard; Angus Clark Nairn
Journal:  Front Neuroanat       Date:  2011-08-26       Impact factor: 3.856

6.  DARPP-32, Jack of All Trades… Master of Which?

Authors:  Marion Yger; Jean-Antoine Girault
Journal:  Front Behav Neurosci       Date:  2011-09-08       Impact factor: 3.558

Review 7.  The involvement of DARPP-32 in the pathophysiology of schizophrenia.

Authors:  Haitao Wang; Mohd Farhan; Jiangping Xu; Philip Lazarovici; Wenhua Zheng
Journal:  Oncotarget       Date:  2017-04-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.